Cellular Targets of Gefitinib
Author:
Affiliation:
1. 1Axxima Pharmaceuticals AG, Munich, Germany and
2. 2Vichem Chemie Ltd. and
3. 3Department of Medicinal Chemistry, Peptide Biochemistry Research Group, Semmelweis University, Budapest, Hungary
Abstract
Publisher
American Association for Cancer Research (AACR)
Subject
Cancer Research,Oncology
Link
https://aacrjournals.org/cancerres/article-pdf/65/2/379/2535561/379-382.pdf
Reference20 articles.
1. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003; 1: 296–313.
2. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004; 10: 1212–8.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–39.
4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004: 304; 1497–500.
5. Godl K, Wissing J, Kurtenbach A, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 2003; 100: 15434–9.
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Current trends and future prospects of drug repositioning in gastrointestinal oncology;Frontiers in Pharmacology;2024-01-04
2. RIPK2 inhibitors for disease therapy: Current status and perspectives;European Journal of Medicinal Chemistry;2023-11
3. Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA);Frontiers in Cardiovascular Medicine;2023-06-16
4. Repurposing Drugs: A New Paradigm and Hopes for Life-threatening Diseases;Drug Repurposing Against SARS-CoV-2;2023-04-12
5. Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases;Frontiers in Pharmacology;2023-03-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3